Skip to main content

SPDR® S&P® Biotech ETF XBI

NAV

NAV

The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

$97.01
as of Nov 14 2024
Base Currency
USD
Assets Under Management
$7,554.69 M
as of Nov 14 2024
Gross Expense Ratio

Gross Expense Ratio

The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.

0.35%

Key Features

  • The SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select IndustryTM Index (the “Index”)
  • Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: Biotechnology
  • Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
  • Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

About this Benchmark

The S&P Biotechnology Select Industry® represents the biotechnology segment of the S&P Total Market Index (“S&P TMI”). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.

Fund Information as of Nov 15 2024

Benchmark S&P Biotechnology Select Industry Index
Inception Date Jan 31 2006
Options Available Yes
Gross Expense Ratio

Gross Expense Ratio

The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.

0.35%
Base Currency USD
Administrator State Street Global Advisors Funds Management Inc.
Investment Manager SSGA Funds Management, Inc.
Management Team Global Equity Beta Solutions
Distributor State Street Global Advisors Funds Distributors, LLC
Distribution Frequency Quarterly

Listing Information as of Nov 15 2024

Exchange Listing Date Trading Currency Ticker CUSIP ISIN
NYSE ARCA EXCHANGE Feb 06 2006 USD XBI 78464A870 US78464A8707

Fund Characteristics as of Nov 14 2024

Est. 3-5 Year EPS Growth

Estimated 3-5 Year EPS Growth

Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.

13.34%
Number of Holdings 145
Price/Book Ratio

Price/Book Ratio

The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.

4.33
Price/Earnings Ratio FY1

Price/Earnings Ratio FY1

The weighted harmonic average of current share price divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.

22.20
Weighted Average Market Cap $25,355.57 M

Index Characteristics as of Nov 14 2024

Est. 3-5 Year EPS Growth 13.34%
Number of Holdings 140
Price/Cash Flow 24.11
Price/Earnings 19.49
Price/Earnings Ratio FY1 22.20

Index Statistics as of Nov 14 2024

Average Size Size Range
Weighted Average Market Cap Mean Median Largest Smallest
$25,369.78 M $9,060.20 M $2,024.43 M $299,754.03 M $213.74 M

Yields as of Nov 14 2024

30 Day SEC Yield

30 Day SEC Yield

(Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the maximum offering price on the last day of the period.

-0.02%
30 Day SEC Yield (Unsubsidized)

30 Day SEC Yield (Unsubsidized)

An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price that does not account for expense ratio waivers.

-
Fund Distribution Yield

Fund Distribution Yield

The sum of the distributions within the past 365 days divided by Net Asset Value per share, expressed as a percentage.

0.15%
Index Dividend Yield

Index Dividend Yield

The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.

0.25%

Fund Market Price as of Nov 14 2024

Bid/Ask

Bid/Ask Mid Point

(Also known as Mid Price) The price between the best price of the sellers for a trading unit of a given security and the best price of the buyer of a trading unit of a given security.

$97.00
Closing Price

Closing Price

Market Price of last reported trade on the exchange.

$96.96
Day High $100.17
Day Low $96.88
Exchange Volume (Shares)

Exchange Volume (shares)

Represents the volume of shares traded on the ETF's primary exchange throughout the previous business day.

3,622,232
Premium/Discount

Premium/Discount to NAV

Shows the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds calculated as ((4PM Bid/Ask - Closing NAV) / Closing NAV * 100)

-0.02%
30-Day Median Bid/Ask Spread

The median bid-ask spread is calculated by identifying national best bid and national best offer ("NBBO") for each Fund as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and posted on each business day.

0.01%

Premium Discount to NAV Graph and Summary

The line graph and table below show historical information about the differences between the daily closing price for shares of the fund (as determined by the fund’s listing exchange) and the fund’s net asset value over certain periods. The vertical axis of the line graph shows the premium/discount expressed as a percentage of NAV. The horizontal axis indicates the date at which the premium/discount occurred. The table shows the number of trading days in which the fund traded at a premium or at a discount to NAV.

Number of Days Summary

Calendar Year 2023 First Quarter of 2024 Second Quarter of 2024 Third Quarter of 2024
Days Traded at Premium

Number of days the ETF 4PM Bid/Ask was above the NAV.

115 23 34 29
Days Traded at Discount

Number of days the ETF 4PM Bid/Ask was below the NAV.

135 38 29 35

Because ETFs trade like stocks at current market prices, shareholders may pay more than a fund’s NAV when purchasing fund shares and may receive less than a fund’s NAV when selling fund shares.

Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257 download a prospectus or summary prospectus now, or talk to your financial advisor. Read it carefully before investing.

Fund Net Cash Amount as of Nov 14 2024

Net Cash Amount $3,615,591.82

Fund Net Asset Value as of Nov 14 2024

NAV

NAV

The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

$97.01
Shares Outstanding 77.88 M
Assets Under Management $7,554.69 M

Fund Performance

  • Fund Inception Date: Jan 31 2006

as of Oct 31 2024

As Of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Jan 31 2006
Fund Before Tax
NAV Oct 31 2024 -1.89% -1.89% 8.83% 46.67% -7.99% 3.61% 5.64% 10.19%
Market Value Oct 31 2024 -1.85% -1.85% 8.83% 46.72% -8.00% 3.61% 5.65% 10.19%
Benchmark
S&P Biotechnology Select Industry Index
Oct 31 2024 -1.88% -1.88% 8.89% 46.86% -7.83% 3.75% 5.64% 10.23%
Fund After Tax
Return after Taxes on Distributions Oct 31 2024 -1.89% -1.89% 8.76% 46.58% -8.01% 3.58% 5.57% 10.10%
Return after Taxes on Distributions and Sale of Fund Shares Oct 31 2024 -1.12% -1.12% 5.22% 27.63% -5.97% 2.79% 4.50% 8.83%
Benchmark
S&P Biotechnology Select Industry Index
Oct 31 2024 -1.88% -1.88% 8.89% 46.86% -7.83% 3.75% 5.64% 10.23%

as of Sep 30 2024

As Of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Jan 31 2006
Fund Before Tax
NAV Sep 30 2024 -2.42% 6.66% 10.92% 35.53% -7.65% 5.42% 6.87% 10.35%
Market Value Sep 30 2024 -2.44% 6.66% 10.88% 35.55% -7.65% 5.41% 6.85% 10.35%
Benchmark
S&P Biotechnology Select Industry Index
Sep 30 2024 -2.38% 6.75% 10.97% 35.58% -7.48% 5.55% 6.84% 10.39%
Fund After Tax
Return after Taxes on Distributions Sep 30 2024 -2.42% 6.65% 10.86% 35.44% -7.66% 5.39% 6.79% 10.26%
Return after Taxes on Distributions and Sale of Fund Shares Sep 30 2024 -1.43% 3.94% 6.46% 21.03% -5.72% 4.22% 5.53% 8.98%
Benchmark
S&P Biotechnology Select Industry Index
Sep 30 2024 -2.38% 6.75% 10.97% 35.58% -7.48% 5.55% 6.84% 10.39%

Past performance is not a reliable indicator of future performance. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Performance of an index is not illustrative of any particular investment.  All results are historical and assume the reinvestment of dividends and capital gains. It is not possible to invest directly in an index.

Performance returns for periods of less than one year are not annualized.  Performance is shown net of fees.

Index returns are unmanaged and do not reflect the deduction of any fees or expenses. Index returns reflect all items of income, gain and loss and the reinvestment of dividends and other income as applicable.

The market price used to calculate the Market Value return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.

Gross Expense Ratio: 0.35%

Top Holdings

Subject to change.

as of Nov 14 2024
as of Nov 14 2024

Fund Top Holdings as of Nov 14 2024

Name Shares Held Weight
INCYTE CORP 3,021,774 3.15%
NATERA INC 1,518,186 3.08%
UNITED THERAPEUTICS CORP 566,388 2.94%
GILEAD SCIENCES INC 2,319,321 2.87%
NEUROCRINE BIOSCIENCES INC 1,571,050 2.59%
VERTEX PHARMACEUTICALS INC 395,711 2.57%
ALNYLAM PHARMACEUTICALS INC 723,993 2.51%
INSMED INC 2,572,540 2.46%
AMGEN INC 577,659 2.29%
SAREPTA THERAPEUTICS INC 1,540,823 2.26%
Download All Holdings: Daily

Index Top Holdings as of Nov 14 2024

Name Weight
Incyte Corporation 3.16%
Natera Inc. 3.08%
United Therapeutics Corporation 2.94%
Gilead Sciences Inc. 2.87%
Neurocrine Biosciences Inc. 2.59%
Vertex Pharmaceuticals Incorporated 2.57%
Alnylam Pharmaceuticals Inc 2.51%
Insmed Incorporated 2.46%
Amgen Inc. 2.30%
Sarepta Therapeutics Inc. 2.26%

Sub-Industry Allocation

as of Nov 14 2024
as of Nov 14 2024

Fund Sub-Industry Allocation as of Nov 14 2024

Sector Weight
Biotechnology 99.92%
Pharmaceuticals 0.05%
Unassigned 0.03%

Index Sub-Industry Allocation as of Nov 14 2024

Sector Weight
Biotechnology 100.00%

Purchase Information

Buying and Selling ETFs

ETFs are flexible and easy to trade. Investors buy and sell them like stocks, typically through a brokerage account. Investors can also employ traditional stock trading techniques; including stop orders, limit orders, margin purchases, and short sales using ETFs. They are listed on major US Stock Exchanges.

ETFs are subject to risk similar to those of stocks including those regarding short-selling and margin account maintenance.

Ordinary brokerage commissions apply.

In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETF shares may be bought and sold on the exchange through any brokerage account, ETF shares are not individually redeemable from the Fund. Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only. Please see the prospectus for more details.

After-tax returns are calculated based on NAV using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor's tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

Unless Otherwise noted all information contained herein is that of the SPDR S&P Biotech ETF.

Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.

Holdings and sectors shown are as of the date indicated and are subject to change. This information should not be considered a recommendation to invest in a particular sector or to buy or sell any security shown. It is not known whether the sectors or securities shown will be profitable in the future.

As with all stocks, you may be required to deposit more money or securities into your margin account if the equity, including the amount attributable to your ETF shares, declines.

The S&P Select Industry series is designed to measure the performance of narrow GICS (Global Industry Classification Standard) sub-industries. The S&P Biotech Select Industry Index is an equal-weighted index that draws constituents from the Biotechnology segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.